


REMARKS

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page(s) is captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



Mary J. Wilson

Reg. No. 32,955

MJW:tat

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE**IN THE CLAIMS**

5. (Amended) An antibiotic composition as claimed in [any one of claims 1 to 4] claim 1 which contains 50mg to 1g of Erythromycin B (or a pharmaceutically acceptable derivative thereof).

7. (Amended) An antibiotic composition as claimed in [any one of claims 1 to 6] claim 1 in the form of a tablet, a capsule, a suspension, an elixir, a syrup or an injectable.

9. (Amended) A pharmaceutical composition as claimed in [any one of claims 1 to 8] claim 1 containing a pharmaceutically acceptable derivative of Erythromycin B and where said derivative is a 2'-ester of Erythromycin B or of Erythromycin B enol ether.

12. (Amended) An ester as claimed in claim [12] 11 which is a succinate ester.

13. (Amended) An antibiotic composition comprising a therapeutically effective amount of an ester as claimed in [any one of claims 10 to 12] claim 10.

17. (Amended) The use as claimed in [any one of claims 13, 14 or 15]
claim 14 in which the microbial infection is TB, Syphilis, Helicobacter pylori, or
Chlamydia.